With the $62B Shire buyout on track, Takeda plans to debut the newly merged company at JPMorgan

After spending the last 6 months lining up the necessary regulatory OKs, Takeda CEO Christophe Weber has scheduled an upcoming shareholder voter needed to seal its $62 billion deal to buy Shire. And aficionados will note the timeline puts the close right in the middle of the industry’s JPMorgan gathering in early January.

Christophe Weber

The US and Japan have already offered their blessings to the buyout, leaving Europe ready to announce its decision by November 20. To get their sign off, Takeda agreed to spin out SHP647 along with “certain associated rights” where the EU saw an overlap with its blockbuster Entyvio. 

With Entyvio growing blockbuster sales, there was never much doubt how that would play out, and the EU sounds ready to give its approval soon.

Now it’s up to Takeda shareholders, who despite a backlash from the Takeda family and a wing of traditionalists at the company are largely expected to line up behind the deal. The vote is now slated for December 5.

Once the company ties up all the remaining loose ends, Takeda expects to complete the acquisition January 8 — right in the middle of the annual JPMorgan confab in San Francisco. That’s the perfect place for the new, global Takeda to debut. 

After that celebration comes the meshing of R&D and marketing machines. You can expect lots of spinouts and deals, and a considerable number of layoffs as well as execs hunt out as many cuts as possible to help pay for the deal.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->